GKOS Stock Gains Following Positive Study Data on iDose Platform

Glaukos (GKOS) recently announced positive data from a new 36-month follow-up analysis of its two Phase 3 pivotal clinical trials evaluating its latest approved product, iDose TR. The company also announced promising data from a phase 4 trial evaluating iDose TR in glaucoma patients. GKOS also provided an update from its ongoing phase 2b/3 trial evaluating its next-generation iDose sustained-release procedural pharmaceutical platform therapy, iDose TREX.The iDose TR is a sustained-release intracameral impla ...